112 related articles for article (PubMed ID: 1708508)
1. Evaluation of a prostacyclin analog, iloprost, and a thromboxane A2 receptor antagonist, daltroban, in experimental intimal hyperplasia.
Levitt MA; Dryjski M; Tluczek J; Bjornsson TD
Prostaglandins; 1991 Jan; 41(1):1-6. PubMed ID: 1708508
[TBL] [Abstract][Full Text] [Related]
2. Effect of enalapril or the thromboxane receptor antagonist, daltroban, in rats with subtotal renal ablation.
Brooks DP; Contino LC; Trizna W; Edwards RM; Ohlstein EH; Solleveld HA
J Pharmacol Exp Ther; 1990 Apr; 253(1):119-23. PubMed ID: 2139468
[TBL] [Abstract][Full Text] [Related]
3. Daltroban blocks thromboxane responses in the pulmonary vascular bed of the cat.
Hood JS; Nossaman BD; Ibrahim IN; McMahon TJ; Babycos CR; Kadowitz PJ
J Appl Physiol (1985); 1992 Jun; 72(6):2305-10. PubMed ID: 1385804
[TBL] [Abstract][Full Text] [Related]
4. Effect of PGI2 and thromboxane antagonist on liver ischemic injury.
Besse T; Gustin T; Claeys N; Schroeyers P; Lambotte L
Eur Surg Res; 1989; 21(3-4):213-7. PubMed ID: 2478369
[TBL] [Abstract][Full Text] [Related]
5. Intrinsic activity of the non-prostanoid thromboxane A2 receptor antagonist, daltroban (BM 13,505), in human platelets in vitro and in the rat vasculature in vivo.
Bertolino F; Valentin JP; Maffre M; Grelac F; Bessac AM; Maclouf J; Delhon A; Lévy-Toledano S; Patoiseau JF; Colpaert FC
Br J Pharmacol; 1995 May; 115(1):210-6. PubMed ID: 7647979
[TBL] [Abstract][Full Text] [Related]
6. Evidence for partial agonist properties of daltroban (BM 13,505) at TP receptors in the anaesthetized open-chest rat.
Bertolino F; Valentin JP; Patoiseau JF; Rieu JP; Colpaert FC; John GW
Naunyn Schmiedebergs Arch Pharmacol; 1997 Oct; 356(4):462-6. PubMed ID: 9349632
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of intimal hyperplasia after arterial injury by heparins and heparinoid.
Dryjski M; Mikat E; Bjornsson TD
J Vasc Surg; 1988 Nov; 8(5):623-33. PubMed ID: 2460647
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of prostaglandin D2 clearance in rat hepatocytes by the thromboxane receptor antagonists daltroban and ifetroban and the thromboxane synthase inhibitor furegrelate.
Pestel S; Nath A; Jungermann K; Schieferdecker HL
Biochem Pharmacol; 2003 Aug; 66(4):643-52. PubMed ID: 12906929
[TBL] [Abstract][Full Text] [Related]
9. Daltroban, a thromboxane receptor antagonist, protects the myocardium against reperfusion injury following myocardial ischemia without protecting the coronary endothelium.
Viehman GE; Ma XL; Lefer AM
Methods Find Exp Clin Pharmacol; 1990 Dec; 12(10):651-6. PubMed ID: 1966110
[TBL] [Abstract][Full Text] [Related]
10. Investigations of the antiatherosclerotic effect of the thromboxane A2 receptor antagonist Daltroban.
Pill J; Wolf O; Schmelz A; Stegmeier K; Metz J
Z Kardiol; 1990; 79 Suppl 3():155-60. PubMed ID: 2151550
[TBL] [Abstract][Full Text] [Related]
11. Thromboxane A2 does not play a role in the development or maintenance of hypertension in spontaneously hypertensive rats.
Stegmeier K; Sponer G; Pill J
Prog Clin Biol Res; 1987; 242():253-7. PubMed ID: 2959964
[No Abstract] [Full Text] [Related]
12. Actions of the novel thromboxane A2 receptor antagonist sodium (E)-11-[2-(5,6-dimethyl-1-benzimidazolyl)-ethylidene]-6,11- dihydrodibenz[b,e]oxepine-1-carboxylate monohydrate on smooth muscle preparations.
Karasawa A; Shirakura S; Higo K; Kubo K
Arzneimittelforschung; 1991 Dec; 41(12):1237-41. PubMed ID: 1815522
[TBL] [Abstract][Full Text] [Related]
13. Pre- and postjunctional effects of some prostanoids in human isolated vas deferens.
Holmquist F; Hedlund H; Andersson KE
Am J Physiol; 1991 Apr; 260(4 Pt 2):R792-7. PubMed ID: 1707245
[TBL] [Abstract][Full Text] [Related]
14. Antiplatelet effects of the novel thromboxane A2 receptor antagonist sodium (E)-11-[2-(5,6-dimethyl-1-benzimidazolyl)-ethylidene]-6,11- dihydrodibenz[b,e] oxepine-2-carboxylate monohydrate.
Karasawa A; Kawakage M; Shirakura S; Higo K; Kubo K; Ohshima E; Obase H
Arzneimittelforschung; 1991 Dec; 41(12):1230-6. PubMed ID: 1840011
[TBL] [Abstract][Full Text] [Related]
15. Effect of thromboxane receptor antagonists on venous thrombosis in rats.
Schumacher WA; Heran CL
J Pharmacol Exp Ther; 1989 Mar; 248(3):1109-15. PubMed ID: 2522985
[TBL] [Abstract][Full Text] [Related]
16. Fibrin glue containing fibroblast growth factor type 1 and heparin with autologous endothelial cells reduces intimal hyperplasia in a canine carotid artery balloon injury model.
Zarge JI; Huang P; Husak V; Kim DU; Haudenschild CC; Nord RM; Greisler HP
J Vasc Surg; 1997 May; 25(5):840-8; discussion 848-9. PubMed ID: 9152311
[TBL] [Abstract][Full Text] [Related]
17. Tumour cell proliferation by thromboxane A2: a receptor-mediated event.
Nigam S; Zakrzewicz A
Adv Prostaglandin Thromboxane Leukot Res; 1991; 21B():925-8. PubMed ID: 1705088
[No Abstract] [Full Text] [Related]
18. Failure of heparin to inhibit the expression of the thrombin receptor following endothelial injury of the rabbit carotid artery.
Guitteny AF; Herbert JM
Eur J Pharmacol; 1997 May; 327(2-3):157-62. PubMed ID: 9200554
[TBL] [Abstract][Full Text] [Related]
19. Thromboxane A2/prostaglandin H2 receptor antagonists.
Le Breton GC; Lim CT; Vaidya CM; Venton DL
Methods Enzymol; 1990; 187():406-14. PubMed ID: 2146463
[No Abstract] [Full Text] [Related]
20. Mechanism of antagonism of thromboxane receptors in vascular smooth muscle.
Yanagisawa A; Smith JA; Brezinski ME; Lefer AM
Eur J Pharmacol; 1987 Jan; 133(1):89-96. PubMed ID: 3030773
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
